SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2015 / Cilt: 45 - Sayı: 2

Quantitative study of epigenetic signature in head >and neck squamous cell carcinoma

Ayesha UMAIR
Bassel TARAKJI
Alzoghaibi IBRAHIM
Azzeghaibi NASSER
Alenzi FQ
Ayesha SHREEN
Pages
372–386
Publication Date
2015-08-13
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Such epigenetic changes have tremendous clinical potential as biomarkers for early cancer detection and therapeutic interventions

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The aberrant upregulation of Forkhead box protein M1 (FOXM1) plays a fundamental role in cancer initiation by perturbing stem cell differentiation.
📊
Key Findings & Data:This study aims to investigate the role of FOXM1 in epigenetic modification and gene expression of target genes in primary human oral keratinocytes, squamous cell carcinoma cell lines, and head and neck squamous cell carcinoma (HNSCC) tissue biopsies.
💡
Conclusion & Impact:Conclusion: Such epigenetic changes have tremendous clinical potential as biomarkers for early cancer detection and therapeutic interventions
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Forkhead box protein M1 · epigenetic modifications · gene expression

Abstract

Background/aim: The aberrant upregulation of Forkhead box protein M1 (FOXM1) plays a fundamental role in cancer initiation by perturbing stem cell differentiation. This study aims to investigate the role of FOXM1 in epigenetic modification and gene expression of target genes in primary human oral keratinocytes, squamous cell carcinoma cell lines, and head and neck squamous cell carcinoma (HNSCC) tissue biopsies. Materials and methods: A genome-wide promoter methylation microarray was used to compare HNSCC cell line (n = 8), primary human oral keratinocytes (NOK; n = 8) transduced with FOXM1 and EGFP, and HNSCC tissue biopsies (n = 3). Seventeen Foxm1B-induced differentially methylated genes were shortlisted. An absolute quantitative polymerase chain reaction was used to validate the differential promoter DNA methylation of each candidate gene induced by FOXM1. These results were compared with the methylation status and altered gene expressions of candidate genes in a panel of genomic DNA and messenger RNA (mRNA) samples previously extracted from HNSCC tissue biopsies. Results: The results were consistent with our hypothesis, showing that aberrant upregulation of FOXM1 expression in in vitro primary NOK induces a global hypomethylation pattern similar to the HNSCC cell line and has an inverse correlation with in vivo mRNA expression levels of HNSCC tissue biopsy. Conclusion: Such epigenetic changes have tremendous clinical potential as biomarkers for early cancer detection and therapeutic interventions

Özet

Background/aim: The aberrant upregulation of Forkhead box protein M1 (FOXM1) plays a fundamental role in cancer initiation by perturbing stem cell differentiation. This study aims to investigate the role of FOXM1 in epigenetic modification and gene expression of target genes in primary human oral keratinocytes, squamous cell carcinoma cell lines, and head and neck squamous cell carcinoma (HNSCC) tissue biopsies. Materials and methods: A genome-wide promoter methylation microarray was used to compare HNSCC cell line (n = 8), primary human oral keratinocytes (NOK; n = 8) transduced with FOXM1 and EGFP, and HNSCC tissue biopsies (n = 3). Seventeen Foxm1B-induced differentially methylated genes were shortlisted. An absolute quantitative polymerase chain reaction was used to validate the differential promoter DNA methylation of each candidate gene induced by FOXM1. These results were compared with the methylation status and altered gene expressions of candidate genes in a panel of genomic DNA and messenger RNA (mRNA) samples previously extracted from HNSCC tissue biopsies. Results: The results were consistent with our hypothesis, showing that aberrant upregulation of FOXM1 expression in in vitro primary NOK induces a global hypomethylation pattern similar to the HNSCC cell line and has an inverse correlation with in vivo mRNA expression levels of HNSCC tissue biopsy. Conclusion: Such epigenetic changes have tremendous clinical potential as biomarkers for early cancer detection and therapeutic interventions

🔖

Cite This Article

UMAIR, A., TARAKJI, B., IBRAHIM, A., NASSER, A., FQ, A., SHREEN, A. (2015). Quantitative study of epigenetic signature in head >and neck squamous cell carcinoma. Turkish Journal of Medical Sciences, Cilt: 45 - Sayı: 2, 372–386. https://ajindex.com/articles/383219

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Daly B, Watt RG, Batchelor P, Treasure ET. Oral Cancer Prevention in Essential Dental Public Health. 1sted. Oxford, UK: Oxford University Press; 2003.
  2. Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 2007; 1775: 92–102.
  3. Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem 2007; 388: 1257–1274.
  4. Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, Sugden D, Thurlow JK, Cheong SC, Teo SH et al. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One 2009; 4: e4849. Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem A, Wan H, Teh MT. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res 2010; 70: 9515–9526.
  5. Yamada Y, Watanabe A. Epigenetic codes in stem cells and cancer stem cells. Adv Genet 2010; 70: 177–199. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6–21.
  6. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008; 454: 766–770.
  7. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057–1068.
  8. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999; 99: 247–257.
  9. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998; 19: 219–220.
  10. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003 Nov; 349: 2042–2054.
  11. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143–153. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148–1159.
  12. Zardo G, Tiirikainen MI, Hong C, Misra A, Feuerstein BG, Volik S, Collins CC, Lamborn KR, Bollen A, Pinkel D et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat Genet 2002; 32: 453–458.
  13. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225–3229.
  14. Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY, Gimlich R, Wong GG, Yao KM. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett 2001; 507: 59–66.
  15. Korver W, Schilham MW, Moerer P,